Efficacy of Tebentafusp-tebn

Tebentafusp-tebn is the first immunotherapeutic agent that contains an engineered T-cell receptor targeting the gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebenforx is the first bispecific T-cell engager to show efficacy in the treatment of advanced solid tumors and the first anti-cancer therapy to demonstrate an overall survival benefit in patients with uveal melanoma (UM).

Although treatment of metastatic cutaneous melanoma (CM) has improved significantly over the past decade, similar improvements have been less pronounced for patients with uveal melanoma, who until recently had a median survival of less than 1 year. To date, no clinical trials of systemic agents have demonstrated a significant survival advantage for patients. A study of 378 adults with advanced uveal melanoma investigated tebenforx and compared it with other drugs (pembrolizumab, ipilimumab, or dacarbazine) . Patients who took tibenforx lived for 21.7 months, while those who took the control drug lived for 16.0 months. Patients who received tebenforx lived an average of 3.3 months before their cancer came back, developed new melanoma, or died, compared with 2.9 months for those who received the comparator drug.

The original drug of Tibenforsi is not currently on the market in China, nor has it been included in medical insurance. After Tebenforx is approved for marketing, there may be less price and other related information. For more drug information and specific prices, please consult a medical consultant.